Infinion Biopharma files draft papers with SEBI for IPO
Infinion Biopharma has filed draft red herring prospectus (DRHP) with the market regulator Securities and Exchange Board of India (SEBI) for an Initial Public Offering (IPO). The IPO comprises the sale of 45 lakh equity shares of Infinion Biopharma.
Proceeds from the IPO will be used towards investment in Mobius Biomedical Inc, acquisition of licenses for product development of skincare and women's health products and working capital requirements. In addition, funds will be used for sales, marketing and distribution expenses for setting up the company's geographical reach and for general corporate purposes. Aryaman Financial Services is the sole book-running lead manager to the issue.
Infinion Biopharma is an innovation-driven life sciences company that combines biophysics and engineering with traditional pharmacology and biochemistry to produce high-value, innovative products across a range of therapeutic areas.
